V03AB15 naloxone

VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes

健保收載品項 TFDA 在效許可證 1 FDA 已核准

台灣藥品與外觀

台灣食藥署在效西藥許可證 1 張;以下列出 1 個品項。

健保收載品名:解麻注射液 0.4公克/公撮、解麻注射液0.4毫克/毫升、鹽酸那囉克松注射液

無外觀照
解麻注射液0.4毫克/毫升

資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。

適應症

台灣 TFDA 核准適應症

  1. 麻醉藥品過量之解毒劑。

美國 FDA 適應症(英文原文對照)

美國 FDA 核准成分 naloxone hydrochloride (商品名 Buprenorphine HCl and Naloxone HCl / Buprenorphine and Naloxone / NALOXONE HYDROCHLORIDE / NARCAN / Naloxone Hydrochloride / Narcan Naloxone HCL) · 仿單更新 2026-04-08

1 INDICATIONS AND USAGE Naloxone HCl Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. Naloxone HCl Nasal Spray is not a substitute for emergency medical care. Limitations of Use: Restrict prescription of naloxone hydrochloride nasal spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. Naloxone HCl Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. ( 1 ) Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. ( 1 ) Naloxone HCl Nasal Spray is not a substitute for emergency medical care. ( 1 )

資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。

健保給付規定

查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。

實證補充

本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。


台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。